Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.

Acute promyelocytic leukemia All-trans-retinoic acid Clonal hematopoiesis Cytopenia of undetermined significance (CCUS) del(20q)

Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 15 04 2019
accepted: 04 09 2019
revised: 03 09 2019
pubmed: 14 9 2019
medline: 11 8 2020
entrez: 14 9 2019
Statut: ppublish

Résumé

A 68-year-old male was diagnosed with acute promyelocytic leukemia (APL). A G-banding chromosomal analysis revealed the co-existence of two clones: one with del(20q) and t(15;17)(q22;q12) and another with del(20q) alone. During the remission of APL following treatment with all-trans-retinoic acid, del(20q) was persistently identified, indicating a diagnosis of cytogenetic abnormalities of undetermined significance (CCAUS) with isolated del(20q). Bicytopenia developed 48 months after the remission of APL. The presence of isolated del(20q) was detected in the G-banding analysis, whereas morphological dysplasia of hematopoietic cells was not confirmed. This case showed indolent progression from CCAUS after the remission of APL to clonal cytopenia of undetermined significance (CCUS). CCUS with isolated del(20q) persisted for 24 months without any finding of hematological malignancies. At the most recent follow-up, targeted capture sequencing showed the U2AF1 S34F mutation. Considerable attention needs to be paid in follow-ups for CCAUS with del(20q) after the treatment of leukemia.

Identifiants

pubmed: 31515708
doi: 10.1007/s12185-019-02731-w
pii: 10.1007/s12185-019-02731-w
doi:

Substances chimiques

Tretinoin 5688UTC01R

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-316

Subventions

Organisme : Japan Society for the Promotion of Science
ID : #17K16189

Références

Int J Hematol. 2017 Jul;106(1):34-44
pubmed: 28555413
J Clin Oncol. 2006 Jun 1;24(16):2456-64
pubmed: 16651647
Nat Rev Cancer. 2017 Jan;17(1):5-19
pubmed: 27834397
Leukemia. 2017 Sep;31(9):1869-1871
pubmed: 28592887
Cancer. 2003 Nov 1;98(9):1905-11
pubmed: 14584073
Int J Lab Hematol. 2018 Aug;40(4):385-391
pubmed: 29624895
Br J Haematol. 1997 Jun;97(4):920-6
pubmed: 9217198
Br J Haematol. 2007 Oct;139(2):265-8
pubmed: 17764468
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
J Clin Oncol. 2006 Jun 1;24(16):2465-71
pubmed: 16651646
Blood. 1996 Jul 1;88(1):59-65
pubmed: 8704202
J Clin Oncol. 2014 Nov 20;32(33):3729-35
pubmed: 25245439
Leuk Res. 2003 Mar;27(3):235-42
pubmed: 12537976
Blood. 2015 Nov 19;126(21):2355-61
pubmed: 26429975
Blood. 2017 Apr 27;129(17):2347-2358
pubmed: 28223278
Br J Haematol. 2014 Mar;164(6):822-33
pubmed: 24372512
Cancer. 2007 Oct 1;110(7):1509-19
pubmed: 17702093

Auteurs

Machiko Fujioka (M)

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.

Hidehiro Itonaga (H)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan. itonaga-ngs@umin.ac.jp.

Takeharu Kato (T)

Department of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Miki Hashimoto (M)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.

Sachie Kasai (S)

Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.

Eo Toriyama (E)

Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.

Rena Kamijo (R)

Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.

Masataka Taguchi (M)

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.

Hiroaki Taniguchi (H)

Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.

Shinya Sato (S)

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.

Sunao Atogami (S)

Department of Laboratory Medicine, Sasebo City General Hospital, Sasebo, Japan.

Yoshitaka Imaizumi (Y)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.

Tomoko Hata (T)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.

Yukiyoshi Moriuchi (Y)

Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yasushi Miyazaki (Y)

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH